CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints

Dow Jones
2024-12-10
 

By Colin Kellaher

 

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

The Boston clinical-stage company said the Phase 2b study didn't meet statistical significance thresholds for its primary endpoint of change in a measure of the disease or any of its key secondary endpoints.

CervoMed said it is pausing all preparations for a planned Phase 3 study until it completes a full analysis of the Phase 2b study results.

Trading in shares of CervoMed, which closed Monday at $10.25, was halted premarket on Tuesday.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

December 10, 2024 07:21 ET (12:21 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10